{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T19:23:14Z","timestamp":1768159394493,"version":"3.49.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005565","name":"Janssen Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008021","name":"Bristol-Myers Squibb Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.clml.2020.04.002","type":"journal-article","created":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T10:58:14Z","timestamp":1586861894000},"page":"602-609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["KRD-PACE Mobilization for Multiple Myeloma Patients With Significant Residual Disease Before Autologous Stem-Cell Transplantation"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1880-7094","authenticated-orcid":false,"given":"Andrew J.","family":"Cowan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0477-1446","authenticated-orcid":false,"given":"Damian J.","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Karami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela S.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6702-9057","authenticated-orcid":false,"given":"Sherilyn","family":"Tuazon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Coffey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa S.","family":"Hyun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward N.","family":"Libby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3277-1910","authenticated-orcid":false,"given":"Leona A.","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.04.002_bib1","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ajh.24402","article-title":"Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.04.002_bib2","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.bbmt.2012.01.008","article-title":"Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies","volume":"18","author":"Sheppard","year":"2012","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.clml.2020.04.002_bib3","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/jca.21360","article-title":"Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"30","author":"Tuchman","year":"2015","journal-title":"J\u00a0Clin Apher"},{"key":"10.1016\/j.clml.2020.04.002_bib4","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.bbmt.2018.02.017","article-title":"Circulating plasma cells at the time of collection of autologous PBSC for transplant in multiple myeloma patients is a negative prognostic factor even in the age of post-transplant maintenance therapy","volume":"24","author":"Cowan","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.clml.2020.04.002_bib5","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00277-013-1911-1","article-title":"Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma","volume":"93","author":"Lee","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2020.04.002_bib6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","article-title":"Total therapy with tandem transplants for newly diagnosed multiple myeloma","volume":"93","author":"Barlogie","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.002_bib7","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1182\/blood-2005-10-4084","article-title":"Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies","volume":"107","author":"Barlogie","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.002_bib8","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2007.06639.x","article-title":"Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3","volume":"138","author":"Barlogie","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.04.002_bib9","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/bjh.12325","article-title":"D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma","volume":"161","author":"Gerrie","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.04.002_bib10","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.leukres.2014.06.024","article-title":"First line and salvage therapy with total therapy 3\u2013based treatment for multiple myeloma\u2014an extended single center experience","volume":"38","author":"Muchtar","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2020.04.002_bib11","doi-asserted-by":"crossref","first-page":"e512","DOI":"10.1038\/bcj.2016.117","article-title":"Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era","volume":"6","author":"Chakraborty","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2020.04.002_bib12","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/10428194.2016.1201572","article-title":"Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma","volume":"58","author":"Chakraborty","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.04.002_bib13","first-page":"982504","article-title":"Bone marrow plasma cell assessment before peripheral blood stem cell mobilization in patients with multiple myeloma undergoing autologous stem cell transplantation","volume":"2014","author":"Lee","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.clml.2020.04.002_bib14","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/sj.bmt.1705307","article-title":"Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients","volume":"37","author":"O\u2019Shea","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.04.002_bib15","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/bmt.2009.176","article-title":"CR represents an early index of potential long survival in multiple myeloma","volume":"45","author":"Wang","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.04.002_bib16","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A\u00a0phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.002_bib17","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A\u00a0phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.002_bib18","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1182\/blood-2012-03-414359","article-title":"An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and\/or refractory multiple myeloma","volume":"119","author":"Vij","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.002_bib19","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1158\/1078-0432.CCR-12-3352","article-title":"Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma","volume":"19","author":"Niesvizky","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.04.002_bib20","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1182\/blood-2016-03-707596","article-title":"Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma","volume":"128","author":"Avet-Loiseau","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.002_bib21","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.04.002_bib22","series-title":"Molecular Pathology in Cancer Research","first-page":"279","article-title":"Flow cytometry for hematologic neoplasms","author":"Wu","year":"2016"},{"key":"10.1016\/j.clml.2020.04.002_bib23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-1-62703-269-8_2","article-title":"Flow cytometry for non-Hodgkin and classical Hodgkin lymphoma","volume":"971","author":"Wu","year":"2013","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.clml.2020.04.002_bib24","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1309\/7371XK6F6P7474XX","article-title":"Identification and purification of classical Hodgkin cells from lymph nodes by flow cytometry and flow cytometric cell sorting","volume":"126","author":"Fromm","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2020.04.002_bib25","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1309\/AJCPW3UN9DYLDSPB","article-title":"Flow cytometry can diagnose classical hodgkin lymphoma in lymph nodes with high sensitivity and specificity","volume":"131","author":"Fromm","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2020.04.002_bib26","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cytob.21178","article-title":"Flow cytometry of ALK-negative anaplastic large cell lymphoma of breast implant\u2013associated effusion and capsular tissue","volume":"88","author":"Wu","year":"2015","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.clml.2020.04.002_bib28","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.04.002_bib29","series-title":"R: A Language and Environment for Statistical Computing","year":"2015"},{"key":"10.1016\/j.clml.2020.04.002_bib30","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/ejh.12843","article-title":"Modified CVAD and modified CBAD compared to high-dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma","volume":"98","author":"Gettys","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2020.04.002_bib31","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.clml.2017.10.008","article-title":"Modified hyperCVAD versus bortezomib-hyperCAD in patients with relapsed\/refractory multiple myeloma","volume":"18","author":"Saraceni","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.04.002_bib32","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.clml.2019.05.001","article-title":"Retrospective review of the use of high-dose cyclophosphamide, bortezomib, doxorubicin, and dexamethasone for the treatment of multiple myeloma and plasma cell leukemia","volume":"19","author":"Tabchi","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.04.002_bib33","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.04.002_bib34","doi-asserted-by":"crossref","first-page":"e616","DOI":"10.1016\/S2352-3026(19)30167-X","article-title":"Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"6","author":"Jackson","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2020.04.002_bib35","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood.V128.22.242.242","article-title":"Consolidation followed by maintenance therapy versus maintenance alone in newly diagnosed, transplant eligible patients with multiple myeloma (MM): a randomized phase 3 study of the European Myeloma Network (EMN02\/HO95 MM Trial)","volume":"128","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.002_bib36","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.04.002_bib37","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clml.2020.04.002_bib38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/10428194.2014.894187","article-title":"The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma","volume":"56","author":"Zinzani","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.04.002_bib39","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJM200506093522321","article-title":"Acute doxorubicin cardiotoxicity","volume":"352","author":"Hayek","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.04.002_bib40","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.pcad.2006.10.002","article-title":"Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management","volume":"49","author":"Takemura","year":"2007","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.clml.2020.04.002_bib41","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.04.002_bib42","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2020.04.002_bib43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.04.002_bib44","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","article-title":"Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies","volume":"98","author":"Siegel","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.04.002_bib45","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and\u00a0dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.04.002_bib46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/ejh.12677","article-title":"\u201cReal-life\u201d experience of preapproval carfilzomib-based therapy in myeloma\u2014analysis of cardiac toxicity and predisposing factors","volume":"97","author":"Danhof","year":"2016","journal-title":"Eur J Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020301804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020301804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:34:47Z","timestamp":1761870887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020301804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S2152265020301804"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.04.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KRD-PACE Mobilization for Multiple Myeloma Patients With Significant Residual Disease Before Autologous Stem-Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}